Hepatocyte-specific Ablation in Zebrafish to Study Biliary-driven Liver Regeneration

Summary

To help assess the molecular mechanisms underlying zebrafish biliary-driven liver regeneration, we established a liver injury model in which the nitroreductase-expressing hepatocytes are genetically ablated upon metronidazole treatment. In this protocol, we describe how to adeptly manipulate, monitor and analyze hepatocyte ablation and biliary-driven liver regeneration.

Abstract

The liver has a great capacity to regenerate. Hepatocytes, the parenchymal cells of the liver, can regenerate in one of two ways: hepatocyte- or biliary-driven liver regeneration. In hepatocyte-driven liver regeneration, regenerating hepatocytes are derived from preexisting hepatocytes, whereas, in biliary-driven regeneration, regenerating hepatocytes are derived from biliary epithelial cells (BECs). For hepatocyte-driven liver regeneration, there are excellent rodent models that have significantly contributed to the current understanding of liver regeneration. However, no such rodent model exists for biliary-driven liver regeneration. We recently reported on a zebrafish liver injury model in which BECs extensively give rise to hepatocytes upon severe hepatocyte loss. In this model, hepatocytes are specifically ablated by a pharmacogenetic means. Here we present in detail the methods to ablate hepatocytes and to analyze the BEC-driven liver regeneration process. This hepatocyte-specific ablation model can be further used to discover the underlying molecular and cellular mechanisms of biliary-driven liver regeneration. Moreover, these methods can be applied to chemical screens to identify small molecules that augment or suppress liver regeneration.

Introduction

The liver is a highly regenerative organ. During liver regeneration, regenerating hepatocytes, the parenchymal cells of the liver, are derived from pre-existing hepatocytes (hepatocyte-driven liver regeneration) or BECs (biliary-driven liver regeneration)^1,2. Liver injury usually elicits the proliferation of pre-existing hepatocytes; however, when hepatocyte proliferation is compromised, BECs can contribute to hepatocytes^2-4. These two modes of liver regeneration are clinically significant. Upon surgical removal of a portion of the human liver (e.g., because of liver tumors or live liver donors), hepatocytes in the remaining liver proliferate to recover the lost liver mass. By contrast, in patients with severe liver diseases, hepatocyte proliferation is greatly compromised, so that BECs or liver progenitor cells (LPCs) appear to contribute to regenerating hepatocytes^5,6. The rodent 2/3 partial hepatectomy model, in which hepatocytes proliferate to recover the lost liver mass, has significantly contributed to the current understanding of hepatocyte-driven liver regeneration^7,8. However, there is no valid rodent model in which regenerating hepatocytes are mainly derived from BECs. Although several rodent liver toxin models led to the identification of biliary-driven liver regeneration^2-4, recent lineage tracing studies in mice indicate a minimal contribution of BECs to regenerating hepatocytes in these models^9,10. Some of the rodent liver injury models, including partial hepatectomy^11-13 and acetaminophen-induced liver damage^14,15, have been applied to zebrafish and led to the identification of novel genes or pathways implicated in liver regeneration. However, hepatocyte-driven, but not BEC-driven, liver regeneration occurs in these zebrafish liver injury models. Therefore, a novel liver injury model in which BECs extensively contribute to regenerating hepatocytes is needed for a better understanding of BEC-driven liver regeneration.

The overall goals of the hepatocyte ablation model described here are (1) to generate a liver injury model in which BECs extensively contribute to regenerating hepatocytes, and (2) elucidate the molecular and cellular mechanisms underlying BEC-driven liver regeneration. We hypothesized that severity of injury determines the mode of liver regeneration; thus, we predicted that biliary-driven liver regeneration would initiate upon severe hepatocyte injury. To test this hypothesis, we developed a zebrafish liver injury model by generating a transgenic line, Tg(fabp10a:CFP-NTR)^s931, that highly expresses bacterial Nitroreductase (NTR) fused with cyan fluorescent protein (CFP) under the hepatocyte-specific fabp10a promoter. Since NTR converts the non-toxic prodrug, metronidazole (Mtz), into a cytotoxic drug, it ablates only the intended NTR-expressing cells^16-18, in this case, the hepatocytes. By manipulating the duration of Mtz treatment, the extent of hepatocyte ablation can be controlled. Using this model, we recently reported that upon severe hepatocyte loss, BECs extensively give rise to regenerating hepatocytes¹⁹, which was further confirmed by two other independent studies^20,21. Therefore, compared to the aforementioned rodent and zebrafish liver injury models, our hepatocyte ablation model is more advantageous for studying BEC-driven liver regeneration.

This protocol describes the procedure for performing liver regeneration experiments using the zebrafish hepatocyte ablation model. This model will be appropriate for determining the mechanisms underlying biliary-driven liver regeneration and for chemical screens to identify small molecules that can repress or augment liver regeneration.

Protocol

Zebrafish were raised and bred according to standard procedure; experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee.

1. Preparation of Embryos/larvae

1. To conduct timed matings, set up adult male and female Tg(fabp10a:CFP-NTR)^s931 hemizygous or homozygous fishes O/N and place a divider between them. Remove this divider the following morning when mating is desired. Collect embryos by straining the water using a fine plastic mesh strainer.
2. Turn the strainer upside down and rinse the mesh surface with a fine stream of egg water dispensed from a squeeze bottle. Transfer 100 embryos into a 100 mm petri dish with 25 ml of egg water. Keep no more than 100 embryos per petri dish and raise them at 28 °C.
3. To inhibit pigmentation, add phenylthiourea (PTU) into the petri dishes prior to 10 hr post-fertilization (hpf), and raise embryos/larvae until 80 hpf. The final concentration of PTU is 0.2 mM. CAUTION: PTU is toxic. Use in accordance with appropriate handling guidelines.
4. Anesthetize the larvae by adding 3-amino benzoic acid ethyl ester (Tricaine), at a final concentration of 0.016%, into the petri dishes. Then, using an epifluorescence microscope, sort CFP-positive larvae. Use larvae with a similar liver size and discard those with a smaller or larger liver.
   NOTE: any CFP-positive larvae, regardless of intensity, can be used because there is no difference in the extent of hepatocyte ablation between the hemizygous and homozygous larvae. CAUTION: tricaine is toxic. Use in accordance with appropriate handling guidelines.
5. Remove the egg water containing Tricaine and add egg water supplemented with 0.2 mM PTU. Keep the embryos/larvae at 28 °C.

2. Mtz Treatment

1. Prepare fresh 10 mM Mtz solution by dissolving 0.171 g of Mtz powder in 100 ml egg water supplemented with 0.2% DMSO and 0.2 mM PTU. To completely dissolve the Mtz, mix the solution at RT with rapid stirring for 20-30 minutes. To help solubilize Mtz and to enhance Mtz permeation into the larvae, add DMSO when preparing Mtz. CAUTION: prolonged exposure or increased concentration of Mtz is toxic. Use in accordance with appropriate handling guidelines.
2. Separate the larvae into control and experimental groups by transferring desired number of larvae into two different 100 mm petri dish or multi-well plate. For the experimental group, keep the larvae in 10 mM Mtz solution; for the control group, keep them in egg water containing 0.2% DMSO.
3. Cover the plates or petri dishes containing the Mtz solution with aluminum foil to prevent the photo-inactivation of Mtz, and incubate at 28 °C. The duration of Mtz treatment depends on the larval stage and the transgenic line.
4. To observe similar severe hepatocyte ablation in the Tg(fabp10a:CFP-NTR) line, treat the larvae with the Mtz solution from either 3.5 days post-fertilization (dpf) (for a duration of 36 hr) or from 5 dpf (for a duration of 24 hr).

3. Analysis of Biliary-driven Liver Regeneration

1. At the end of the ablation period, remove the Mtz solution from the plates. Wash the Mtz-treated larvae by adding 25 ml of egg water. Swirl the plate 2-3 times to wash the larvae before discarding the egg water. Repeat three times and then immerse the larvae once more in egg water. To avoid heart edema and larval death in the Mtz-treated larvae, add a lower concentration of Tricaine, at a final concentration of 0.008%, to immobilize the larvae.
2. For liver analysis, examine the liver size of the Mtz-treated larvae under an epifluorescence microscope with the CFP filter. Assess hepatocyte ablation levels based on the relative liver size: large (non-ablated; 0-10% larvae), medium (partially ablated; 10-20%), and very small (fully ablated; 80-90%).
3. Remove the larvae with non-ablated or partially ablated livers. Only keep larvae with a tiny liver, which is indicative of severe hepatocyte ablation. For liver analysis at the regeneration 0 hr time point (R0h), harvest the larvae after Mtz washout and CFP sorting. Otherwise, keep the sorted larvae in egg water supplemented with 0.2 mM PTU until ready for harvesting.
4. Transfer harvested larvae into a 1.5 ml microcentrifuge tube and replace egg water with the fixation solution of 3% formaldehyde in PEM buffer. Incubate the tube on a rotator O/N at 4 °C.
5. Replace the fixation solution with 1 ml of PBSDT and rotate the tube containing the larvae on the rotator for 5 min.
6. Transfer the fixed larvae into a 100 mm petri dish containing PBSDT and using forceps, manually remove yolk and pectoral fins under a dissecting microscope. Transfer up tp 20 dissected larvae into a 1.5 ml tube.
7. Replace PBSDT solution with 1 ml of blocking solution and rock the tube on a rotator at RT for 2 hr.
8. Replace blocking solution with 100 µl of blocking solution containing primary antibodies. Slowly rock the tube on a rotator O/N at 4°C.
9. Remove the primary antibody solution and wash with PBSDT 5 times for 10 min each time. Then add 100 ul of blocking solution containing secondary antibodies and rock it on a rotator at RT for 2hr.
10. Wash 5 times with PBSDT for 10 min each time at RT by rocking on a rotator.
11. Orient the larvae laterally on a microscope slide and add a drop of mounting media. Carefully cover them with a cover glass and seal the cover glass with a nail polisher. Now, it is ready for confocal microscopy.

Results

Mtz treatment for 36 hr (A36h, A stands for ablation) from 3.5 to 5 dpf dramatically reduced liver size (Figure 1B). After Mtz washout, considered as the beginning of liver regeneration (R), strong fabp10a:CFP-NTR and fabp10a:dsRed expression reappeared within 30 hr (Figure 1B). The intrahepatic biliary network, as assessed by expression of Alcam that is present in the membrane of BECs²², initially collapsed but was re-established at 54 hr post-washout (R54h)...

Discussion

Severe, but not mild, hepatocyte ablation elicits biliary-driven liver regeneration. Therefore, following Mtz treatment and washout, it is important to examine the liver size of the Mtz-treated larvae, which can be assessed by intrinsic CFP fluorescence from the fabp10a:CFP-NTR transgene. Since a small percentage of the Mtz-treated larvae will display non-ablated (0-5%) or partially ablated (10-20%) livers, it is essential to sort out and only analyze the larvae with a very small liver, which is indicative of se...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
3-amino benzoic acid ethyl ester (Tricaine) powder	Sigma-Aldrich	A5040	Make 0.4% (15 mM) tricaine stock : Bring 0.4 g tricaine to 100 mL with egg water. Adjust to pH 7.
Dimethyl sulfoxide (DMSO)	Sigma-Aldrich	D8418
Metronidazole	Sigma-Aldrich	M1547
Triton X-100	Sigma-Aldrich	T8532
Formaldehyde	Sigma-Aldrich	252549
Calcium sulfate dihydrate	Sigma-Aldrich	C3771
N-Phenylthiourea (PTU)	Sigma-Aldrich	P7629
Mounting media (Vectashield)	Vector Laboratories	H-1000
100 x 15 mm petri dish	Denville Scientific Inc.	M5300
clear nail polish	Fisher Scientific	50949071
fine forceps	Fine Science Tools	11251-20	Dumont #5
glass slide	Fisher Scientific	12-544-1
glass coverslip	Fisher Scientific	12-540-A and 12-542-A	18 x 18 mm
zn-5 (mouse anti-Alcam)	ZIRC	zn-5	1:10 dilution
goat anti-Hnf4a	Santa Cruz	sc-6556 (C-19)	1:50 dilution
rat anti-RFP	Allele Biotechnology	ACT-CM-MRRFP10	1:300 dilution
AlexaFluor 647 AffiniPure Donkey Anti-goat IgG (H+L)	Jackson laboratories	705-605-147	1:500 dilution
AlexaFluor 647 AffiniPure Goat Anti-mouse IgG (H+L)	Invitrogen	A21240	1:500 dilution
Cy3 donkey anti-rat IgG	Jackson laboratories	712-165-150	1:500 dilution
dissecting microscope	Leica Microsystems	S6F
epifluorescence microscope	Leica Microsystems	M205FA
confocal microscope	Carl Zeiss	LSM700
egg water			0.3 g/L of sea salts ‘Instant Ocean’ and 0.5 mM CaSO4 in distilled water.
[header]
10X PBS			25.6 g Na2HPO4·7H2O, 80 g NaCl, 2 g KCl, 2 g KH2PO4.  Bring to 1 L with distilled water.  Adjust pH 7.  Autoclave for 20 min at 121°C.
1X PBSDT			0.2% Triton X-100 and 0.2% DMSO in 1 X PBS.
PEM buffer			30.2 g PIPES, 761 mg EGTA, 1 mM MgSO4.  Bring to 1 L with distilled water.  Adjust pH 7.
Blocking solution			Mix 1 ml of heat-inactivated horse serum with 9 ml of 1X PBSDT.